← Back to headlines
Positive Trial Results for Pharvaris, Roivant, and Genflow Biosciences
Several biotech companies reported positive clinical trial data, including Pharvaris' drug for hereditary angioedema, Roivant's mosliciguat, and Genflow's SLAB trial, boosting their stock prices.
8 Sept, 06:31 — 8 Sept, 11:51
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (47/100)4 sources30/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center3
Center (3)
investing-comtaiwan-newsmorningstar
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US3Taiwan1
Sources
Showing 3 of 4 sources
morningstar6h ago
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met - Morningstar
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met Morningstar
Read full article →seeking-alphaMixed1h ago
Pharvaris rises on late-stage trial win for hereditary angioedema drug
Read full article →taiwan-newsMostly Factual2h ago
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks - Taiwan News
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks Taiwan News
Read full article →Coverage Timeline
First report: morningstar · 8 Sept, 06:31|Full coverage: 4 · 5h|Window: 5h
Left-leaningCenterRight-leaning
